vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Madison Square Garden Sports Corp. (MSGS). Click either name above to swap in a different company.
Madison Square Garden Sports Corp. is the larger business by last-quarter revenue ($403.4M vs $281.3M, roughly 1.4× Guardant Health, Inc.). Madison Square Garden Sports Corp. runs the higher net margin — 2.0% vs -45.7%, a 47.7% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 12.8%). Madison Square Garden Sports Corp. produced more free cash flow last quarter ($31.6M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -3.1%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Madison Square Garden Sports Corp. is an American sports holding company based in New York City.
GH vs MSGS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $403.4M |
| Net Profit | $-128.5M | $8.2M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 5.5% |
| Net Margin | -45.7% | 2.0% |
| Revenue YoY | 39.4% | 12.8% |
| Net Profit YoY | -15.8% | 641.9% |
| EPS (diluted) | $-1.01 | $0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $403.4M | ||
| Q3 25 | $265.2M | $39.5M | ||
| Q2 25 | $232.1M | $204.0M | ||
| Q1 25 | $203.5M | $424.2M | ||
| Q4 24 | $201.8M | $357.8M | ||
| Q3 24 | $191.5M | $53.3M | ||
| Q2 24 | $177.2M | $227.3M | ||
| Q1 24 | $168.5M | $430.0M |
| Q4 25 | $-128.5M | $8.2M | ||
| Q3 25 | $-92.7M | $-8.8M | ||
| Q2 25 | $-99.9M | $-1.8M | ||
| Q1 25 | $-95.2M | $-14.2M | ||
| Q4 24 | $-111.0M | $1.1M | ||
| Q3 24 | $-107.8M | $-7.5M | ||
| Q2 24 | $-102.6M | $25.5M | ||
| Q1 24 | $-115.0M | $37.9M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | 5.5% | ||
| Q3 25 | -37.3% | -69.5% | ||
| Q2 25 | -45.9% | -11.1% | ||
| Q1 25 | -54.6% | 7.6% | ||
| Q4 24 | -62.4% | 3.7% | ||
| Q3 24 | -61.3% | -15.5% | ||
| Q2 24 | -56.8% | 23.0% | ||
| Q1 24 | -59.2% | 18.5% |
| Q4 25 | -45.7% | 2.0% | ||
| Q3 25 | -35.0% | -22.3% | ||
| Q2 25 | -43.0% | -0.9% | ||
| Q1 25 | -46.8% | -3.4% | ||
| Q4 24 | -55.0% | 0.3% | ||
| Q3 24 | -56.3% | -14.1% | ||
| Q2 24 | -57.9% | 11.2% | ||
| Q1 24 | -68.2% | 8.8% |
| Q4 25 | $-1.01 | $0.34 | ||
| Q3 25 | $-0.74 | $-0.37 | ||
| Q2 25 | $-0.80 | $-0.08 | ||
| Q1 25 | $-0.77 | $-0.59 | ||
| Q4 24 | $-0.90 | $0.05 | ||
| Q3 24 | $-0.88 | $-0.31 | ||
| Q2 24 | $-0.84 | $1.07 | ||
| Q1 24 | $-0.94 | $1.57 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $81.3M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $-282.1M |
| Total Assets | $2.0B | $1.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $81.3M | ||
| Q3 25 | $580.0M | $48.6M | ||
| Q2 25 | $629.1M | $144.6M | ||
| Q1 25 | $698.6M | $96.5M | ||
| Q4 24 | $525.5M | $107.8M | ||
| Q3 24 | $585.0M | $52.3M | ||
| Q2 24 | $933.7M | $89.1M | ||
| Q1 24 | $1.0B | $40.0M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $-282.1M | ||
| Q3 25 | $-354.5M | $-294.2M | ||
| Q2 25 | $-305.5M | $-281.4M | ||
| Q1 25 | $-250.8M | $-283.4M | ||
| Q4 24 | $-139.6M | $-273.1M | ||
| Q3 24 | $-60.1M | $-277.5M | ||
| Q2 24 | $-1.6M | $-266.3M | ||
| Q1 24 | $68.3M | $-294.0M |
| Q4 25 | $2.0B | $1.5B | ||
| Q3 25 | $1.3B | $1.5B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.5B | ||
| Q4 24 | $1.5B | $1.4B | ||
| Q3 24 | $1.5B | $1.4B | ||
| Q2 24 | $1.6B | $1.3B | ||
| Q1 24 | $1.7B | $1.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $32.4M |
| Free Cash FlowOCF − Capex | $-54.2M | $31.6M |
| FCF MarginFCF / Revenue | -19.3% | 7.8% |
| Capex IntensityCapex / Revenue | 9.9% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 3.94× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $-480.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $32.4M | ||
| Q3 25 | $-35.4M | $-85.0M | ||
| Q2 25 | $-60.3M | $49.7M | ||
| Q1 25 | $-62.7M | $6.3M | ||
| Q4 24 | $-64.5M | $61.8M | ||
| Q3 24 | $-51.1M | $-26.2M | ||
| Q2 24 | $-94.0M | $108.4M | ||
| Q1 24 | $-30.3M | $4.0M |
| Q4 25 | $-54.2M | $31.6M | ||
| Q3 25 | $-45.8M | $-85.3M | ||
| Q2 25 | $-65.9M | $49.4M | ||
| Q1 25 | $-67.1M | $3.9M | ||
| Q4 24 | $-83.4M | $61.2M | ||
| Q3 24 | $-55.3M | $-26.5M | ||
| Q2 24 | $-99.1M | $108.0M | ||
| Q1 24 | $-37.2M | $3.9M |
| Q4 25 | -19.3% | 7.8% | ||
| Q3 25 | -17.3% | -216.3% | ||
| Q2 25 | -28.4% | 24.2% | ||
| Q1 25 | -33.0% | 0.9% | ||
| Q4 24 | -41.3% | 17.1% | ||
| Q3 24 | -28.9% | -49.7% | ||
| Q2 24 | -55.9% | 47.5% | ||
| Q1 24 | -22.1% | 0.9% |
| Q4 25 | 9.9% | 0.2% | ||
| Q3 25 | 3.9% | 0.9% | ||
| Q2 25 | 2.4% | 0.2% | ||
| Q1 25 | 2.2% | 0.6% | ||
| Q4 24 | 9.4% | 0.1% | ||
| Q3 24 | 2.2% | 0.7% | ||
| Q2 24 | 2.9% | 0.2% | ||
| Q1 24 | 4.1% | 0.0% |
| Q4 25 | — | 3.94× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 55.61× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 4.25× | ||
| Q1 24 | — | 0.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
MSGS
| Event Related | $167.2M | 41% |
| Media Rights | $122.3M | 30% |
| Sponsorship Signage And Suite Licenses | $98.5M | 24% |
| League Distribution | $15.4M | 4% |
